Year: 2016
Type: article
Abstract: We read with great interest the recent article by Zheng et al. describing the STICS clinical trial testing whether perioperative rosuvastatin administration lowers rates of postoperative atrial fibrillation (AF) and myocardial infarction after coronary artery bypass grafting (CABG) or CABG plus aortic valve surgery (1). These are important questions because we know that postoperative AF after cardiac surgery has significant implications on health care outcomes and costs (2). Notably, the STICS study revealed no difference in postoperative AF rates between placebo and rosuvastatin treated groups.
Source: Journal of Thoracic Disease
Authors: Tyler P. Rasmussen, Prashant D. Bhave
Institutions: University of Iowa, University of Iowa Health Care
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2512396558